Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Just to repost this excellent post from last night by user Beforegolf:
This was posted tonight by well respected, working A&E consultant. He agreed it could be shared. Slightly edited because of size limit.
I still can't get my head around LTH holders selling out at this point . After holding we're possibly 6 weeks away or less from Synairgen unequivocally showing the world that sng001 is a highly effective treatment both IN & OUT of hospital. Oh & we're at a rock bottom SP. Am I missing something?
P3 hospital:
Progression to severe disease
PP
517
32 (12.3%) - placebo
20 (7.8%) - sng
36% risk reduction, p = 0.11
Just consider this. 10% of the entire PP progressed to severe disease. Out of 517 patients, 52 people progressed to severe disease. That means 450 people diluted our results by not progressing to severe disease and made our results insignificant.
The question is can we cut away some of the 450 PP trial participants that are diluting our results without removing those that progressed to severe disease.
From the SG018 Protocol:
The following subgroups will be considered for analysis:
• Age
• comorbidities
• smoking
• Sex
• Race
• Prior duration of symptoms
• BMI
Now the ones who progressed to severe disease are most likely: Elderly, unvaccinated, those with co-morbidities & those who presented late.
It's likely that both young people (under 40s) & people without co-morbidities did not progress to severe disease so we can eliminate those in the subanalysis.
20% of patients fully vaccinated & a further 15% had 1 dose . Considering the vaccine reduces the odds of Progression to severe disease this is another population you could cut out.
Sng can mix and match these to find the perfect fit/population where the most benefit & showed significance.
If you could keep the PP 32 placebo patients who progressed to severe disease & 20 on sng who progressed or even the ITT 46 placebo who progressed & 33 on sng who progressed but cut the trial population down to 300 - 400 the results should show significance. They have a multitude of ways to do that WITH scientific backing I.e natural interferon production is impaired in older people, who have co-morbidities & aren't fully vaccinated (2 dose) which is why when we ran the analysis in this population we found significant results in...
Activ 2:
Hard virological evidence that sng is a potent inhibitor of viral load in the airway. When activ 2 patients use the nebuliser where is sng accumulating the most? The back of the throat. Where are the PCR swabs swabbing to measure viral load for activ 2 study? Back of the throat. Can't see an IV mAb beating that.
Irregardless the market will finally see evidence sng reduces reduces viral load in patients and that sng isn't worth the 7-8p it's valued at now given that the cash value alone of the company is 12.4p.
Throw in terms like viral agnostic, broad spectrum, Sir Stephen Holgate & the share price should be higher than 2
I fully agree BG and thank you for sharing. It’s mind blowing that LTH are selling out after P3 topline data. Theres still so much on offer here which, I believe Polygon also know. This deserves to be reposted first thing tomorrow!
This is great news considering the situation. We are the only ones still on the trial. Looks like we will have deep dive sprinter data pretty soon and SNG001 has strong potency against delta and omicron. Nice rise today please!
Not sure if this has been mentioned but have we seen the new Medusa webpage?
https://www.medusahealthcare.co.uk/
“How would we feel if RM comes out to say the findings are hugely significant.....!“
Yes thats kind of what i was getting at and although not meeting the endpoints due to improvement of standard care from P2, a 40% reduction in death IS a significant finding.
Given this was ‘topline’ data we have had about not meeting end points, is there scope to totally change things once results have been analysed carefully? Seems very odd that we are in this situation after all the evidence and years of work/data.